Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite

被引:34
|
作者
Sparidans, Rolf W. [1 ]
Vlaming, Maria L. H. [2 ]
Lagas, Jurjen S. [2 ]
Schinkel, Afred H. [2 ]
Schellens, Jan H. M. [1 ,2 ]
Beijnen, Jos H. [1 ,2 ,3 ]
机构
[1] Univ Utrecht, Fac Sci, Dept Pharmaceut Sci, Sect Biomed Anal,Div Drug Toxicol, NL-3584 CA Utrecht, Netherlands
[2] Netherlands Canc Inst, Dept Med Oncol & Expt Therapy, NL-1066 CX Amsterdam, Netherlands
[3] Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
关键词
Sorafenib; Sorafenib-glucuronide; LC/MS/MS; Mouse plasma; Mouse liver homogenate; RAF KINASE INHIBITOR; CARCINOMA; VALIDATION; DRUG;
D O I
10.1016/j.jchromb.2008.12.026
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The first bioanalytical assay for the simultaneous determination of sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate was developed and validated. In addition, the structure of the glucuronide metabolite was elucidated. The quantitative assay started with addition of isotopically labeled internal standards to a 20 mu l sample volume and protein precipitation with acetonitrile, the supernatant was diluted with water and injected into the chromatographic system. A polar embed-ded reversed-phase column with gradient elution using formic acid in water-acetonitrile was used. The eluate was transferred into an electrospray interface with positive ionization and the analytes were detected and quantified using triple quadrupole mass spectrometry. The assay was validated in the ranges 10-5000 ng/ml for sorafenib and 1-500 ng/ml for sorafenib-glucuronide, the lowest levels of these ranges (10 and 1 ng/ml) being the lower limits of quantification (LLQ). Within day precisions were 2-8%, between day precisions 2-10% (both excluded the LLQ level of the glucuronide) and accuracies were between 89% and 106%. Both analytes were chemically stable under all relevant conditions. The assay was successfully applied in pilot in vivo pharmacokinetic studies with sorafenib in mice. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:269 / 276
页数:8
相关论文
共 50 条
  • [1] Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N+-glucuronide in plasma
    Sparidans, Rolf W.
    Durmus, Selvi
    Xu, Ning
    Schinkel, Alfred H.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 895 : 169 - 173
  • [2] Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method
    Wang, Ling-Zhi
    Lee, Lawrence Soon-U
    Thuya, Win-Lwin
    Soon, Gaik Hong
    Kong, Li-Ren
    Nye, Pei-Ling
    Lee, Edmund Jon Deoon
    Flexner, Charles
    Goh, Boon-Cher
    JOURNAL OF MASS SPECTROMETRY, 2011, 46 (02): : 202 - 208
  • [3] Simultaneous quantification of tizoxanide and tizoxanide glucuronide in mouse plasma by liquid chromatography-tandem mass spectrometry
    Liu, Jinqiu
    Meng, Fanhua
    Li, Zhaofeng
    Yu, Lin
    Peng, Shuangqing
    Guo, Jifen
    Xu, Haiyan
    BIOMEDICAL CHROMATOGRAPHY, 2016, 30 (11) : 1744 - 1749
  • [4] Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry
    Li, Lie
    Zhao, Ming
    Navid, Fariba
    Pratz, Keith
    Smith, B. Doug
    Rudek, Michelle A.
    Baker, Sharyn D.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2010, 878 (29): : 3033 - 3038
  • [5] Nonalcoholic steatohepatitis increases plasma retention of sorafenib-glucuronide in a mouse model by altering hepatocyte hopping
    Toth, Erica
    Li, Hui
    Frost, Kayla
    Sample, Paxton
    Jilek, Joseph
    Greenfield, Siennah
    You, Dahea
    Kozlosky, Danielle
    Goedken, Michael
    Paine, Mary F.
    Aleksunes, Lauren
    Cherrington, Nathan
    ACTA PHARMACEUTICA SINICA B, 2024, 14 (11) : 4874 - 4882
  • [6] Validated liquid chromatography-tandem mass spectrometric method for the quantitative determination of daidzein and its main metabolite daidzein glucuronide in rat plasma
    Chen, XY
    Qiu, F
    Zhong, DF
    Duan, XT
    Liu, CX
    PHARMAZIE, 2005, 60 (05): : 334 - 338
  • [7] A liquid chromatography-tandem mass spectrometric method for quantification of curcumin-O-glucuronide and curcumin in human plasma
    Chen, Wei
    Fan-Havard, Patty
    Yee, Lisa D.
    Cao, Yu
    Stoner, Gary D.
    Chan, Kenneth K.
    Liu, Zhongfa
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 900 : 89 - 93
  • [8] Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma
    Sparidans, Rolf W.
    Tang, Seng Chuan
    Nguyen, Luan N.
    Schinkel, Alfred H.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 905 : 150 - 154
  • [9] Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples
    Papini, O
    Bertucci, C
    da Cunha, SP
    dos Santos, NAG
    Lanchote, VL
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2006, 40 (02) : 389 - 396
  • [10] Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma
    Sparidans, Rolf W.
    Durmus, Selvi
    Schinkel, Alfred H.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2013, 925 : 124 - 128